Boehringer Ingelheim agreed to participate in the administration’s drug‑pricing initiative and to join the TrumpRx.gov purchasing platform while committing $10 billion to expand U.S. R&D and manufacturing through 2028. The pact includes a $1 billion capital expenditure component and an exemption from potential Section 232 tariffs to preserve medicine access. Separately, Boehringer inked a collaboration with Boston startup Rectify to develop oral therapies for chronic kidney disease in a deal worth up to $448 million. The partnership targets oral small molecules for CKD and aligns with Boehringer’s announced U.S. investment drive. These moves position Boehringer as a major pharmaceutical partner to U.S. policy initiatives and highlight the company’s strategy of pairing policy engagement with domestic manufacturing investment and external R&D alliances.